Novo Challenges Order To Trim Prandin Patent

Law360, New York (October 1, 2009, 1:51 PM EDT) -- Novo Nordisk Inc. has appealed an injunction forcing the drugmaker to amend key use code in its patent for the diabetes treatment Prandin in litigation seeking to block Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. from manufacturing a generic version.

In a notice of appeal filed Tuesday in the U.S. District Court for the Eastern District of Michigan, Novo challenged the injunction, which requires the drug manufacturer to amend the “inaccurate description” it submitted to the U.S. Food and Drug Administration setting out the...
To view the full article, register now.